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ABSTRACT
Objective: Evaluate the effectiveness of secondary screening using non-invasive prenatal testing 
(NIPT) in a routine NHS setting including test performance, turn-around times (TATs) and no-call 
(failure to obtain result) rates. To examine the influence of maternal and fetal characteristics on 
test performance.
Design: Retrospective cohort
Setting: London teaching hospital
Sample: 8651 pregnancies undergoing screening for fetal trisomy using NIPT provided by an 
NHS cell-free DNA screening laboratory – the SAFE laboratory 
Methods: Screening test evaluation and TATs. Univariate and multivariate logistic regression 
analysis to identify significant predictors of no-call results and reported by low fetal fraction(<2%), 
very high fetal fraction(>40%) and processing failure.
Main outcome measures: Test performance, TATs and no-call rates, factors affecting no-call 
results.
Results: Average TAT was 4.0 days(95% CI 4.0–4.2). Test sensitivities for trisomy 21 and 13/18 
were 98.9%(95%CI 95.9 – 99.9) and 90.4%(95%CI 80.0 – 96.8), respectively. The overall no-call 
rate was 32/8651(0.37%, 95%CI 0.26–0.52%). The overall risk of a no-call result was influenced 
by gestational age, dichorionic twin pregnancy, history of malignancy and pregnancies affected 
by trisomy 18/13, but not by maternal weight or use of low molecular weight heparin.
Conclusions: High-throughput NIPT can be effectively embedded into a public health NHS 
setting. TATs of 4 days and no-calls of <0.5% were well within clinically desirable tolerances. 
Gestational age, maternal weight, assisted reproductive techniques, use of LMW heparin and 
past history of malignancy did not have major impact on test no-call rates and should not 
constitute reasons for withholding the option of NIPT from women.
Funding:  None.A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
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Tweetable abstract: “Turn-around times of 4 days and no-call (test failure) rates of 0.37%, highly 
accurate NIPT can be successfully embedded in the NHS”
What we already know:
 Commercial and research studies have demonstrated that NIPT is effective in both high 
and low-risk populations.
What this study adds:
 High-throughput NIPT can be successfully embedded in a public health setting.
 Screening performance of NIPT in the NHS matches that published in research settings.
 Test turn-around times of 4 days and no-call rates of 0.37% are well within clinically 
desirable tolerances.
 Gestational age, maternal weight, assisted reproductive techniques, use of LMW heparin 
and history of malignancy have a negligible influence on test no-call rates.
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INTRODUCTION
The United Kingdom National Screening Committee (UKNSC) recommended a secondary 
screening model where women with a high-chance (≥1:150) combined or quadruple test result for 
fetal trisomy were to be offered non-invasive prenatal testing (NIPT), invasive testing or expectant 
management1. Despite a large number of studies reporting on NIPT, most are not comparable to 
a public health setting as they have been conducted in a research context2,3,4 undertaken by 
private laboratories with incomplete reporting of maternal variables and pregnancy outcomes5,6 or 
largely undertaken in low-risk populations7. Furthermore, there is a paucity of data on the impact 
of various maternal and pregnancy characteristics on routine NIPT performance in secondary 
screening. In view of these limitations, National Health Service England (NHSE) and Public 
Health England (PHE) recommended in 2018 that an evaluative role out of secondary NIPT 
screening as outlined in the UKNSC recommendations should be commissioned to establish 
specifically test turn-around times, rates and reasons for no-calls (failure to obtain a result) as 
well as test performance in the detection of the three common fetal trisomies1. We report on the 
performance of secondary NIPT screening conducted entirely in a UK public health setting from a 
large cohort of pregnancies. The aim of this study is to first, evaluate the effectiveness of NIPT in 
a routine NHS setting with regards to test performance, turn-around times and no-call rates; and 
second, to examine the effects of maternal and fetal characteristics, obstetric history and medical 
history on no-call results.
METHODS
St George's University Hospitals NHS Foundation Trust implemented a non-invasive prenatal test 
(the SAFE test) laboratory service in November 2015. The data for this study were derived from a 
retrospective analysis of prospectively collected data from the clinical implementation of the 
SAFE test in secondary screening for fetal trisomy between January 2016 and March 2019. As 
such, patients were not involved in the development of the research and there was no funding 
necessary to undertake the analysis. Samples originated from secondary screening for a high 
chance (>1:150) combined screening result or screen positive quadruple test in the SAFE test 
collaborative  network (a total of fourteen NHS trusts) and women electing to undertake self-pay 
NIPT via NHS or private healthcare providers after either a low chance (<1:150) combined test 
result or no prior screening (a total of thirteen providers). Referral centres reported the high 
chance combined or quadruple test result, without details of specific biochemical or nuchal A
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translucency measurements and only occasionally reported the presence of major fetal 
abnormalities. Pregnancies with very high risks (>1:10) were not excluded from SAFE test 
analysis as this was not an automatic indication for invasive testing. Healthcare professionals 
were encouraged to undertake the free online training module: ‘Non-Invasive Prenatal Testing 
(NIPT): An Introduction for Healthcare Professionals’ prior to sending samples to ensure 
adequate collection and result interpretation8.
Blood was collected in a single 10ml STRECK (Cell-free DNA BCT CE) tube labelled with three 
patient identifiers. This was stored and transported to the laboratory for processing at room 
temperature (6-37oC). The SAFE test procedural workflow is CE-IVD certified and was divided 
into the following steps: plasma separation and cell-free fetal deoxyribonucleic acid (cfDNA) 
extraction; automated library construction; automated emulsion polymerase chain reaction (PCR); 
Library DNA sequencing and automated data analysis. This resulted in a processing time of 35 h 
for up to 32 samples, in multiples of eight, for optimal throughput9. The ensuing fragment count 
data were used as the input to a set of mixture models, which incorporated distributions of 
expected values for both trisomy-affected and unaffected samples. The models generated test 
likelihood ratios to quantify the relative likelihood that the DNA fragment count data supported a 
trisomy-affected or unaffected result for each trisomy under consideration.
Validity checks also took place for each sample that ensured that the aligned fragment count was 
sufficient for the likelihood mixture model to be used, and secondly that the proportion of cfDNA 
in the sample that was of fetal origin was sufficient (>2%) for a result to be reported. For a fetal 
fraction (FF) between 2-4%, the SAFE test utilised a ‘dynamic range test’ which applied an 
algorithm using fetal fraction, depth of sequencing and a-priori trisomy risk to determine the fetal 
fraction threshold to permit reporting10. A no-call result was also issued for a high cfDNA fetal 
fraction of more than 40% and a technical failure (failed chip, not enough plasma, low fragment 
count). In response to a no-call result, we undertook a repeat test by using the same blood 
sample – not by requesting a redraw. The advantage of using the Ion Proton device is that only 
small volumes are required for sequencing, thereby permitting a rerun using spare stored serum 
which can be completed often within three days.
Outcome Measures
Maternal and pregnancy characteristics, results of the cfDNA testing and pregnancy outcome 
were obtained from the SAFE test and outcome database. Details collected included maternal 
demographic characteristics, method of conception (spontaneous or artificial reproductive A
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technology), maternal history (including previous malignancy), medication (including low 
molecular weight heparin (LMWH)) and sample origin (UK or non-UK based). Gestational age 
and chorionicity (in case of twin pregnancy) was determined by ultrasound performed by the 
referring centre. A vanishing twin was classified as ultrasound evidence of two gestational sacs 
with only one viable fetus identified. All referring centres used an internet portal for requesting 
tests and accessing results. The portal was also used to ascertain pregnancy outcome for the 
purposes of mandatory reporting on screening audits. The pregnancy outcomes were divided into 
non-trisomic, T21 or T18 or T13 by either confirmed karyotype (n=219) or phenotypical normality 
of the neonate. All abnormal karyotype results were cross checked with regional cytogenetic 
registers to ensure accuracy. Other core pregnancy outcomes, unrelated to NIPT, were not 
available as these were not routinely collected. Pregnancies lost to follow-up or with incomplete 
reporting of outcomes were not included in the analysis. 
Statistical analysis
Descriptive data were presented in median and interquartile range for continuous variables and in 
numbers and percentages for categorical variables. Comparisons between groups were 
performed using the Mann–Whitney U‐test for continuous variables and the χ2 test or Fisher's 
exact test for categorical variables. In the combined data of those with and without no-call results, 
univariate logistic regression analysis was used to determine which of the factors amongst 
maternal weight, height, history of malignancy, use of LMWH, gestational age at sampling, 
method of conception, origin of sample, type of pregnancy (singleton or dichorionic or 
monochorionic or vanishing twin) and fetal karyotype (non-trisomic or T21 or T18/13) were 
significant predictors of no-call test results (n=32). To reduce the risk of over modelling the data, 
combinations of these factors were used in multivariate logistic regression analysis, where 
complete data were available (n=3,347), to determine the two/three most significant predictors of 
no-call results.  For subgroup analysis, this process was repeated for no-call results secondary to 
low fetal fraction (n=18). Due to the low number of cases of no-call results secondary to high fetal 
fraction (n=9) and technical problems (n=5), a univariate analysis using Fisher's exact and Mann-
Whitney U test was performed. The statistical software package SPSS 22.0 (SPSS Inc., Chicago, 
IL) and GraphPad (GraphPad Software, San Diego, CA) were used for data analyses.
RESULTS
Study populationA
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Between January 2016 and March 2019, the SAFE Test laboratory analysed 8655 samples, of 
which 8651 samples had outcomes (Table 1). The performance characteristics of the SAFE test 
are shown in Table 2. The average turn-around time (TAT) for the SAFE test was 4.0 days (IQR 
4.0 – 4.2) with only 2 days of unplanned downtime out of 1094 service days. The test sensitivities 
for trisomy 21 and 13/18 were 98.9% (95%CI 95.9 – 99.9) and 90.4% (95%CI 80.0 – 96.8), 
respectively. The equivalent positive predictive values for trisomy 21 and 13/18 were 96.7% 
(95%CI 92.8 – 98.4) and 92.2% (95%CI 81.5 – 96.9), respectively. The overall no-call rate 
following a second attempt of laboratory processing was 32/8651 (0.37%, 95%CI 0.26 – 0.52%). 
The majority of trisomy 21 or trisomy 13/18 pregnancies were in the high-chance population 
rather than the self-selected referrals. There were 110 (66%) T21 and 38 (73%) T13/18 from the 
high-chance group and 57 (33%) T21 and 14 (27%) T13/18 from the self-pay group. In 
pregnancies identified as high chance (n=252), 177 (70%) had prenatal invasive testing, with the 
remainder opting for post-natal confirmation by phenotypical normality of the neonate or 
karyotype if trisomy was suspected.  The rates of trisomy 21 and 13/18 pregnancies in those with 
no-call results were 2/32 (6.3%, 95%CI 0.8 – 22.6) and 4/32 (12.5%, 95%CI 3.4 – 32.0), 
respectively. Of the women with no-call results, 7/32 (21.9%, 95%CI 10.7 – 39.0) had prenatal 
invasive testing, 6/32 (18.8%, 95%CI 8.5 – 35.7) had a successful blood re-draw and 19/32 
(59.4%, 95%CI 42.2 – 74.5) opted for post-natal confirmation of karyotype. 
Factors influencing no-call results
Multivariate logistic regression analysis demonstrated that the overall risk of a no-call result was 
influenced by dichorionic twin pregnancy, history of malignancy and pregnancies affected by 
trisomy 18/13, but not maternal weight or use of low molecular weight heparin (Table 3). Low fetal 
fraction resulted in a no-call result in 18/8651 samples (0.21%, 95%CI 0.13 – 0.33%). Multivariate 
logistic regression analysis demonstrated that the risk of a no-call result due to low fetal fraction 
was higher with increased with maternal weight (Figure 1), in dichorionic twins, and pregnancies 
affected by T18 or T13 (Table S1). No-calls due to high fetal fraction occurred in 9/8651 (0.10%, 
95%CI 0.05 – 0.20) pregnancies and was influenced by maternal height, gestational age and 
maternal history of malignancy (Table S2). Technical reasons for no-calls occurred in 5/8651 
(0.06%, 95%CI 0.02 – 0.14) samples, which occurred more frequently in samples originating from 
outside the UK and in pregnancies affected by T18 or T13 (Table S2).
DISCUSSIONA
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Main findings
This study demonstrates the feasibility and effectiveness of a high-throughput NIPT secondary 
screening service embedded in a public health NHS setting. The screening performance of the 
SAFE test with sensitivities of 98.9% for trisomy 21 and 90.4% for trisomy 18/13, are comparable 
to those from studies published in research settings or in commercially funded trials. The SAFE 
test also performed well with a median turn-around time of four days, and only two days of 
unplanned downtime in over three years of service. In a secondary screening model, NIPT is 
offered as an alternative to expectant management and invasive prenatal testing after a primary 
screening by first trimester combined test or early second trimester maternal serum biochemical 
screening. The latter care pathway inevitably leads to NIPT being performed at a more advanced 
gestation compared to the use of NIPT as a primary screening test. In the clinical context of 
secondary screening, fast turn-around times and fewer laboratory downtime days are an 
essential attribute for a high-throughput NIPT laboratory.
Strengths and limitations of the study
This is one of the first studies to evaluate the effectiveness of secondary NIPT screening in a 
large population of women undergoing routine care in a non-research setting and therefore offers 
unique and pragmatic insights into practical issues regarding implementation of cfDNA screening 
in a public health system. Although a large study, the very low overall test no-call rate made it 
difficult to validate previously reported modulators of the test no-call rate. For instance, maternal 
history of malignancy was linked to only one no-call resulting in an odds ratio with large 
confidence interval and low level of precision. There is also the possibility that no-call variables 
may be different in a low risk population, such as self-referring women who may already have a 
low chance screening result. Although further data will be needed to confirm the significance of 
patient characteristics related to no-calls, it is reassuring to know they resulted in very few test 
failures. Whilst we are able to report on the number of women referred to our centre for invasive 
testing in the studies population, we do not have access to data on women who were not referred 
for invasive testing or were referred elsewhere for further management. Therefore, we are unable 
to report on the effect of secondary screening on the overall screening programme nor on the 
potential weakness of a secondary versus primary NIPT screening in reducing the false positive 
rate at the cost of a slight reduction in the population detection rate.
Interpretation
Low fetal fraction no-callsA
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The majority of institutional and societal guidelines recommend that fetal fraction is measured 
when undertaking NIPT to ensure that fetal DNA is present in sufficient quantity in the maternal 
sample to enable a technically reliable estimate of fetal trisomy risk11,12. Most NIPT providers set 
a fixed fetal fraction threshold (usually 4%) below which a no-call result is issued. The 
consequence of a set reporting threshold is that these NIPT tests usually have a 2-5% no-call 
rate. The no-call rate for low fetal fraction with the SAFE test (0.21%) is much lower than 
previously reported for NIPT that measure fetal fraction. The latter is almost certainly due to the 
use of a dynamic range that allows reporting down to fetal fractions as low as 2.5% - as long as 
the fragment count is high enough to provide reliable likelihood ratios for fetal trisomy. The lower 
no-call rate is an important attribute in a secondary screening program of high-chance women to 
minimise any delays in providing NIPT results in women who are further advanced in pregnancy 
compared to primary NIPT screening. It is also reassuring to find that the relative lower no-call 
rate is not associated with a concomitant drop in the sensitivity and specificity for fetal trisomy.
Low fetal fraction no-calls were more likely to occur with increased maternal weight, dichorionic 
pregnancy and trisomic pregnancies – consistent with the findings of previous review 
publications13,14. Although the odds ratios for these factors varied from 8-fold up to 36-fold, the 
absolute probabilities of no-call results were low. For example, the risk of a no-call result was only 
1% in women weighing over 90kg (Figure 1). Similarly, the overall risk of a no-call in a dichorionic 
pregnancy was 1.4%. Importantly, low fetal fraction no-call results were more likely in 
pregnancies affected by T18 and T13, in keeping with previous evidence15 and probably as a 
consequence of the smaller placental size and lower levels of circulating fetal cfDNA in these 
pregnancies. Due to the increased risk of no-call results in trisomic pregnancies, consideration 
should be given to offer invasive testing to these women. Reassuringly, use of LMWH did not 
result in higher no-call rates – contrary to a previous report that the majority of no-calls were from 
women on LMWH16. The authors suggested that plasma samples had a curiously elevated levels 
of short fragment length cfDNA that biased test results. An alternative hypothesis for the putative 
test failure is that LMWH is a known inhibitor of polymerase chain reaction (PCR) which may 
reduce the amount of DNA amplification required in the NIPT process17. However, our study 
suggests that women may use LMWH without affecting cfDNA test no-call rates or performance. 
The caveat to this conclusion is that the majority of our women were on lower dose prophylactic 
LMWH rather than high dose therapeutic LMWH – for which there is possibly a higher risk of no 
call result18.
Technical and high fetal fraction no-callsA
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Only samples from non-UK based centres had an increased risk of technical failure resulting in 
no-calls. This is a centre-specific finding which may be due to the technique of sampling, handling 
of samples, massive temperature fluctuations and delays in transport. The risk of a technical 
failure was also higher with trisomy 18/13, but this finding is based on only one no-call test result. 
Similarly, a solitary case contributed to an increase in high fetal fraction no-call associated with a 
maternal history of malignancy. The concentration of circulating cfDNA is known to be increased 
in patients with malignant disorders probably as a consequence of increased cell turnover and 
death and release of cfDNA into the circulation19.
Conclusions
High-throughput NIPT can be effectively undertaken and clinically embedded into routine NHS 
practice. Screening performance of NIPT in the NHS setting matches that published in research 
settings. Test turn-around times of 4 days and low no-call rate of <0.5% were well within 
expected clinical tolerances. Gestation, maternal weight, assisted reproductive techniques, LMW 
heparin use and history of malignancy did not have major impact on test no-call rates and should 
not constitute reasons for withholding the option of NIPT.
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Table 1. Maternal and pregnancy characteristics of the tested population.
Characteristic Tests with results (n=8651)
      Maternal height (cm) 165 (160 – 170)
      Maternal weight (kg) 65.0 (58.6 – 75)
      Maternal age (yrs) 34.6 (31.1 – 38.1)
      Gestation at sampling (weeks) 12.0 (11.0 – 14.0)
Conception 
      Spontaneous 7881 (91.1%)
      Artificial reproductive technology 770 (8.9%)
Medical history
      History of malignancy 23 (0.3%)
      Use of LMW Heparin 248 (2.9%)
Sample origin
      UK 7812 (90.3%)
      Non-UK 837 (9.7%)
Type of pregnancy
      Singleton 8289 (95.8%)
      DC twin 213 (2.5%)
      MC twin 41 (0.5%)
      Vanishing twin 108 (1.2%)
Number of trisomy pregnancies
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      Trisomy 21 167 (1.9%)
      Trisomy 18/13 52 (0.6%)
Data presented as median (interquartile range) or number (%). ART, artificial reproductive 
technology; DC, dichorionic; LMW, low molecular weight; MC, monochorionic, UK, United 
Kingdom; T21, Down’s Syndrome; T18/13: Edward’s and Patau’s Syndromes, yrs; years.
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Table 2. Performance of the SAFE test 
Number (%), Number (%, 95% CI) or median (IQR)
Indication
      High-chance prior screen 3017 (35%)
      Self-pay tests 5634 (65%)
Turn-around time (days) 4 (4 – 4.2)
Retesting rate 164, (1.9%, 1.6 – 2.2)
No-call rate
      Overall 32, (0.37%, 0.26 – 0.52)
      Low fetal fraction 18, (0.21%, 0.13 – 0.33)
      High fetal fraction 9, (0.10%, 0.05 – 0.20)
      Technical failure 5, (0.06%, 0.02 – 0.14)
Test performance
      Overall false positive rate 10, (0.12%, 0.02 – 0.22)
      T21 sensitivity 173/175 (98.9%, 95.9 – 99.9)
      T21 positive predictive value 96.7% (92.8 – 98.4)
      T18/13 sensitivity 47/52 (90.4%, 80.0 – 96.8)
      T18/13 positive predictive value 92.2% (81.5 – 96.9)
Data presented as median (interquartile range) or number (%). T21, trisomy 21, T18/13, trisomy 
18 or 13
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Table 3. Univariate and multivariate logistic regression analyses of factors from maternal and 
pregnancy characteristics in the prediction of overall no-call results (n = 32) in 8651 (univariate) 
and 3348 (multivariate) pregnancies. The following were used as reference populations: 
spontaneous conceptions for ART pregnancies, UK samples for non-UK samples, singleton for 
twin pregnancies and non-trisomic fetuses for trisomic fetuses.
Variable
Univariate analysis
Odds ratio
(95% CI)
P 
value
Multivariate analysis
Adjusted Odds ratio
(95% CI)
P 
value
Maternal Height (cm) 0.987 (0.939 – 1.038) 0.611 x x
Maternal Weight (kg) 1.018 (0.999 – 1.037) 0.059 x x
Gestational Age 1.091 (1.021 – 1.165) 0.010* x x
Medical history
ART pregnancies 1.657 (0.579 – 4.741) 0.346 x x
History of 
malignancy
13.754 (1.723 – 109.800) 0.013* 17.265 (2.144 – 139.036) 0.007*
Use of LMWH 1.600 (0.217 – 11.796) 0.645 x x
Sample origin
Non-UK 2.162 (0.887 – 5.268) 0.090 x x
Type of pregnancy
DC Twin 4.142 (1.252 – 13.704) 0.020* 5.275 (1.565 – 17.785) 0.007*
MC Twin -- -- x x
Vanishing twin -- -- x x
Fetal Karyotype
T21 3.414 (0.809 – 14.405) 0.095 x xA
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T18 or 13 24.974 (8.442 – 73.880) <0.001* 33.029 (10.616 – 102.762) <0.001*
--: OR not calculated due to lack of no-call cases. ART, artificial reproductive technology; DC, dichorionic; 
LMWH, low molecular weight heparin; MC, monochorionic, UK, United Kingdom; T21, Down’s Syndrome; 
T18/13: Edward’s and Patau’s Syndromes
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Figure 1. Cross and whisker plots showing the no-call rate for low fetal fraction with maternal 
weight in 10Kg blocks for the cohort of 8651 tests.
A
cc
ep
te
d 
A
rt
ic
le
bjo_16464_f1.tiff
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
